Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Eur J Intern Med ; 112: 100-108, 2023 06.
Artículo en Inglés | MEDLINE | ID: mdl-37003923

RESUMEN

INTRODUCTION: Medical cannabis is an increasingly prevalent treatment for a wide variety of indications, yet there is still no uniformly accepted protocol for the titration of cannabinoid doses. We aimed to develop a model to predict the stable THC and CBD dosages after six months of treatment using available baseline patient characteristics. METHODS: In this prospective study, we included all consecutive adult patients (age 18 and above) who exclusively used a single method of cannabis delivery. Telephone interviews were conducted six months post-treatment initiation to assess changes in symptoms and side effects. We prospectively analyzed THC and CBD dosages with respect to demographic variables and patient characteristics in two main groups divided according to cannabis administration method - inhalation or sublingual oil. RESULTS: A total of 3,554 patients were included in the study (2,724 exclusively inhaled cannabis and 830 exclusively consumed cannabis as sublingual oil). The daily THC and CBD doses were significantly higher in the inhalation group than in the sublingual group (p<.001). None of the four models predicting THC and CBD doses in the two groups had satisfactory prediction ability (adjusted R-squared between 0.007 and 0.09). Male gender, unemployed status, tobacco smoking and a lack of concern about cannabis treatment were associated with a higher inhaled THC dose (p<.001). CONCLUSION: Models based on patient characteristics failed to accurately predict the final titration doses of CBD and THC for both inhalation and sublingual administration. Clinical guidelines should maintain a highly individual approach for cannabinoid dosing.


Asunto(s)
Cannabinoides , Cannabis , Marihuana Medicinal , Adulto , Humanos , Masculino , Adolescente , Estudios Prospectivos , Dronabinol , Marihuana Medicinal/efectos adversos
2.
Parkinsonism Relat Disord ; 61: 211-213, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30292733

RESUMEN

INTRODUCTION: Patients with Gilles de la Tourette syndrome (GTS) experience reduced function and impaired quality of life. The current medical treatments for this syndrome can cause significant side effects and offer partial symptomatic relief. In a few small trials medical cannabis (MC) has been suggested to offer symptomatic relief with a relatively benign side effect profile. We conducted a real-life assessment of clinical benefit and adverse effects of chronic MC treatment among patients with GTS. METHODS: GTS patients treated with MC were interviewed via phone regarding treatment efficacy and side effect profile from chronic MC consumption. Global efficacy was rated on a Likert scale of 1-5 and side effects of treatment were recorded. RESULTS: Forty-Two GTS patients (33 males, mean age 34.5) were interviewed for this study. The total global impression score of efficacy was 3.85 out of a total 5 possible points. Patients reported during the free discussion part of the interview about reduction in tic severity, better sleep and improved mood as positive effects of MC. Thirty-eight patients reported any kind of benefit from treatment while 10 patients with more than one year of consumption elected to stop treatment with MC for various reasons including severe side effects as psychosis in one patient. CONCLUSION: MC seems to hold promise in the treatment of GTS as it demonstrated high subjective satisfaction by most patients however not without side effects and should be further investigated as a treatment option for this syndrome.


Asunto(s)
Agonistas de Receptores de Cannabinoides/farmacología , Marihuana Medicinal/farmacología , Síndrome de Tourette/tratamiento farmacológico , Adulto , Anciano , Agonistas de Receptores de Cannabinoides/administración & dosificación , Agonistas de Receptores de Cannabinoides/efectos adversos , Femenino , Humanos , Masculino , Marihuana Medicinal/administración & dosificación , Marihuana Medicinal/efectos adversos , Persona de Mediana Edad , Resultado del Tratamiento , Adulto Joven
3.
Eur J Intern Med ; 49: 44-50, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-29398248

RESUMEN

INTRODUCTION: There is a substantial growth in the use of medical cannabis in recent years and with the aging of the population, medical cannabis is increasingly used by the elderly. We aimed to assess the characteristics of elderly people using medical cannabis and to evaluate the safety and efficacy of the treatment. METHODS: A prospective study that included all patients above 65 years of age who received medical cannabis from January 2015 to October 2017 in a specialized medical cannabis clinic and were willing to answer the initial questionnaire. Outcomes were pain intensity, quality of life and adverse events at six months. RESULTS: During the study period, 2736 patients above 65 years of age began cannabis treatment and answered the initial questionnaire. The mean age was 74.5 ±â€¯7.5 years. The most common indications for cannabis treatment were pain (66.6%) and cancer (60.8%). After six months of treatment, 93.7% of the respondents reported improvement in their condition and the reported pain level was reduced from a median of 8 on a scale of 0-10 to a median of 4. Most common adverse events were: dizziness (9.7%) and dry mouth (7.1%). After six months, 18.1% stopped using opioid analgesics or reduced their dose. CONCLUSION: Our study finds that the therapeutic use of cannabis is safe and efficacious in the elderly population. Cannabis use may decrease the use of other prescription medicines, including opioids. Gathering more evidence-based data, including data from double-blind randomized-controlled trials, in this special population is imperative.


Asunto(s)
Analgésicos Opioides/uso terapéutico , Dolor en Cáncer/tratamiento farmacológico , Dolor Crónico/tratamiento farmacológico , Marihuana Medicinal/uso terapéutico , Calidad de Vida , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Israel , Masculino , Marihuana Medicinal/efectos adversos , Dimensión del Dolor , Estudios Prospectivos , Resultado del Tratamiento
4.
J Child Neurol ; 33(9): 565-571, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29766748

RESUMEN

A complex motor disorder is a combination of various types of abnormal movements that are associated with impaired quality of life (QOL). Current therapeutic options are limited. We studied the efficacy, safety, and tolerability of medical cannabis in children with complex motor disorder. This pilot study was approved by the institutional ethics committee. Two products of cannabidiol (CBD) enriched 5% oil formulation of cannabis were compared: one with 0.25% δ-9-tetrahydrocannabinol (THC) 20:1 group, the other with 0.83% THC 6:1 group. Patients aged 1 to 17 years (n = 25) with complex motor disorder were enrolled. The assigned medication was administered for 5 months. Significant improvement in spasticity and dystonia, sleep difficulties, pain severity, and QOL was observed in the total study cohort, regardless of treatment assignment. Adverse effects were rare and included worsening of seizures in 2 patients, behavioral changes in 2 and somnolence in 1.


Asunto(s)
Marihuana Medicinal/uso terapéutico , Trastornos Motores/tratamiento farmacológico , Trastornos Motores/psicología , Calidad de Vida/psicología , Adolescente , Niño , Preescolar , Electroencefalografía , Femenino , Humanos , Lactante , Pruebas de Función Hepática , Masculino , Evaluación de Resultado en la Atención de Salud , Índice de Severidad de la Enfermedad , Escala Visual Analógica
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA